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Trastuzumab was added to the South African (SA) Essential Medicines 
List (EML) in 2017 for the adjuvant management of human epidermal 
growth factor receptor 2 (HER2)-positive early breast cancer.[1] In 
support of this decision, the National Department of Health, via the 
National EML Committee (NEMLC), developed a clinical criteria 
document to guide the judicious use of this expensive medicine in 
eligible patients. To this end, a loading dose of 8 mg/kg, followed by 
6 mg/kg, administered 3-weekly for 12 months (17 - 18 cycles), as 
used in the HERA (HERceptin Adjuvant) trial,[2] was stipulated. 
Notwithstanding its inclusion on the EML, access to trastuzumab 
has remained inconsistent, as some provinces continue to regard it 
as unaffordable within the contexts of their respective oncology 
budgets.[3] Therefore, the intention of providing access to trastuzumab 
by including it on the EML has not been met.
Duration of therapy and unintended 
consequences
The optimal duration of trastuzumab therapy in the adjuvant 
management of early HER2-positive breast cancer has been 
contentious for many years.[4-7] The standard of care has been to 
prescribe therapy over a 12-month period[8] based on the findings of 
the pivotal licensing trials, including the HERA trial,[2] as well as the 
NSABP B31 and NCCTG N9831 trials.[9] Importantly, it has since 
been noted that this treatment duration was selected arbitrarily.[8,10] 
Moreover, courses >1 year increase the risk of harm[8] and offer no 
advantage in terms of disease-free or overall survival.[2,11-13] 
With breast cancer being the most common cancer in women, 
comprising 20 - 25% of cancers,[14,15] and HER2 being overexpressed 
in ~25% of patients with early breast cancer,[16] the cost of therapy 
and the resource implications for managing and monitoring patient 
response have resulted in the unintended consequence of increasing 
inequity of access, as there continues to be variable access to 
trastuzumab among provinces.
Rationale for EML future review
The EML process includes ongoing monitoring and evaluation 
to ensure the relevance and applicability of policy decisions. The 
NEMLC terms of reference require expert review committees (ERCs) 
to review newly published peer-reviewed information within the 
context of any predefined review indicators. The Tertiary/Quaternary 
ERC’s original review of trastuzumab listed the following review 
indicators:
• randomised controlled trials (RCTs) investigating the impact of 
shorter trastuzumab treatment periods on clinical effectiveness 
and safety 
• RCTs investigating the optimal dosing schedule of trastuzumab 
treatment with different chemotherapy regimens 
• pricing changes, including the introduction of generic products 
and biosimilars. 
Several articles[8,17-22] investigating shorter treatment durations for 
trastuzumab have been published subsequent to this initial review. 
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Consequently, the Tertiary/Quaternary ERC’s 
most recent review was commissioned to 
assess the impact of a shorter trastuzumab 
treatment period on clinical efficacy and 
safety.
New data
The PERSEPHONE study[8] was an open-
label randomised phase-3 non-inferiority 
trial that investigated whether 6-month 
adjuvant trastuzumab treatment was non-
inferior to the standard 12-month treat-
ment regarding disease-free survival. A 
total of 4 089 female patients aged ≥18 years, 
with a diagnosis of invasive early HER2-
positive breast cancer, were randomised 
to receive either 12 months (n=2 045) 
or 6 months (n=2 044) of trastuzumab 
treat ment. The patient population was 
considered to be hetero geneous: <5% had 
a primary tumour >5 cm in size; >60% 
had a tumour grading of 3 (poorly differ-
entiated); <15% demonstrated ≥N2 nodes 
(i.e. >4 positive nodes); and ~40% received 
only anthra cyclines.
Both treatment regimens were delivered 
intravenously every 3 weeks (loading dose 
of 8 mg/kg, followed by maintenance doses 
of 6 mg/kg) or subcutaneously (600 mg), 
given in combination with chemotherapy 
(concurrently or sequentially). The primary 
endpoint was disease-free survival, analysed 
by intention to treat, with a non-inferiority 
margin of 3% for 4-year disease-free survival. 
Secondary endpoints included overall 
survival and cardiac function as assessed 
by left ventricular ejection fraction (LVEF) 
during treatment. Patients were followed up 
for a median of 5.4 years. 
The 4-year disease-free survival was 
89.4% in the 6-month group and 89.8% in 
the 12-month group (hazard ratio (HR) 1.07 
(90% confidence interval (CI) 0.93 - 1.24); 
non-inferiority; p=0.011). The absolute 
difference in overall survival between 
treatment groups at 4 years was 1%, and 
was found to be non-inferior (4-year overall 
survival of 94.8% in the 12-month group and 
93.8% in the 6-month group). The HR for 
overall survival was 1.14 (90% CI 0.95 - 1.37; 
non-inferiority; p=0.001, with a prespecified 
non-inferiority HR of 1.6).
From a safety perspective, there were 
significantly fewer severe adverse events 
associated with the 6-month regimen 
(n=373/1 939 (19%) patients v. n=459/1 894 
(24%) patients; p=0.0002). Furthermore, 
the 6-month regimen was associated with 
fewer patients terminating the study owing 
to cardiotoxicity (n=61/1 939 (3%) patients 
v. n=146/1 894 (8%) patients; p<0.0001).
The PHARE (Protocol for Herceptin as 
Adjuvant therapy with Reduced Exposure) 
study,[23] which was published in 2013, 
provides a worthwhile reference point for 
the findings of PERSEPHONE.[8] Although 
PHARE failed to meet its prespecified 
non-inferiority margins, the magnitude 
of benefit observed in this study lends 
credence to the extent of benefit observed in 
PERSEPHONE. PHARE was also an open-
label, randomised, phase-3 trial and involved 
3 384 female patients with HER2-positive 
early breast cancer. It compared 6 months 
with 12 months of trastuzumab therapy 
(administered by intravenous infusion 
every 3 weeks; initial loading dose 8 mg/kg; 
6 mg/kg thereafter). Patients were followed 
up for a median duration of 3.5 years. The 
2-year disease-free survival was 93.8% in the 
12-month group and 91.1% in the 6-month 
group (HR 1.28; 95% CI 1.05 - 1.56; p=0.29). 
From a safety perspective, more patients in 
the 12-month group experienced a cardiac 
event than those in the 6-month group 
(n=96/1 690 (5.7%) patients v. n=32/1 690 
(1.9%) patients; p<0.0001).
Six meta-analyses[17-22] were consi dered 
for this review; however, none met the 
inclusion requirements. They were either 
of low quality in terms of methodologi-
cal rigour and/or failed to include the 
results from key clinical trials. One 
study[21] was published prior to the finali-
sation of the PERSEPHONE study, while 
another[22] excluded the results from the 
PERSEPHONE, PHARE and HORG 
(Hellenic Oncology Research Group)[10] 
studies. Four studies[17-20] did not stratify for Figure 1:  Updated clinical criteria for access to trastuzumab 
UPDATED CLINICAL CRITERIA FOR ACCESS TO TRASTUZUMAB 
 
Access to be available in line with clinical criteria mentioned below, at authorised sites, 
prescribed by authorised prescriber (medical and/or radio- oncologist). 
 
 
Indication 
• ! Adjuvant treatment of HER-2 positive early stage breast cancer 
Exclusions: 
• ! Patients with locally advanced or metastatic breast cancer 
• ! T1N0M0 
• ! Patients with clinically significant comorbid diseases  
• ! Cardiac ejection fraction < 55% 
• ! Significant hepatic or renal dysfunction 
• ! ECOG Performance Status > 1 
• ! Patients who have only received adjuvant hormonal therapy with no adjuvant 
chemotherapy 
• ! Pregnancy or lactation 
 
Tests and screening 
• ! Invasive breast cancer diagnosis (Biopsy specimen or histology of surgically resected 
specimen – segmentectomy or mastectomy) 
• ! HER2 – positive 3+ OR HER2 – positive 2+/FISH positive 
• ! Left ventricular ejection fraction (LVEF) evaluation  55% 
 
Access to be available in line with clinical criteria mentioned below, 
at authorised sites, prescribed by authorised prescriber 
(medical and/or radio-oncologist)
I i ti
• Adjuvant trea m nt of HER2-positive early-stage breast c ncer
E l si s
• Patients with locally advanced or metastatic breast cancer
• T1N0M0
• Patients with clinically signicant comorbid diseases
• Cardiac ejection fraction <55%
• Signicant hepatic or renal dysfunction
• ECOG performance status >1
• Patients who have received only adjuvant hormonal therapy with no adjuvant chemotherapy
• Pregnancy or lactation
 
Regimen 
Medicine Trastuzumab 
Route Intravenous infusion 
Dose 
Initial 8mg/kg  (week 1) 
Maintenance 6mg/kg  (from week 4) 
Dosing cycle 3 weekly 
Duration 6 months 
        Medicine                                        Trastuzumab
              Route                                 Intravenous infusion
               Initial                                    8 mg/kg (week 1)
Maintenance                              6 mg/kg (from week  4)
 Dosing cycle                                            3-weekly
        Duration                                            6 months
Dose
Monitoring and treatment
• 3-weekly follow-up for consult and treatment
• LVEF tests – baseline and at 6 months
Tests and screening
• Invasive breast cancer diagnosis (biopsy specimen or histology of surgically resected 
   specimen – segmentectomy or mastectomy)
• HER2-positive 3+ or HER2-positive 2+/FISH-positive
• LVEF evaluation ≥55%
Regimen
Fig. 1. Updated clinical criteria for access to trastuzumab. (HER2 = human epidermal growth factor 
receptor 2; TNM = tumour, node, metastasis; ECOG = Eastern Cooperative Oncology Group; 
FISH = fluorescence in situ hybridisation; LVEF = left ventricular ejection fraction.)
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9 weeks and 6 months; therefore, the results for all short-duration 
therapy were consolidated and compared with those for 12 months. 
In a context where the absolute margins of difference are small, 
these articles do not assist in answering the question at hand.
Conclusions and updated NEMLC 
policy stance
The 12-month duration of therapy that became the de facto standard 
of care is recognised as having been selected arbitrarily. Moreover, 
prolonged exposure to trastuzumab increases the risk of cardiotoxicity. 
In this context, the PERSEPHONE study[8] presents important new 
data from a large patient cohort, demonstrating non-inferiority 
of 6-month v. 12-month duration. It also confirms that therapy of 
shorter duration is associated with a halving of the cardiovascular 
risk. We note that the numerical difference in effect size between the 
6-month and 12-month treatment regimens is small and consistently 
observed across various non-inferiority studies.[8,23] Therefore, in the 
interests of improving access while reducing both cost and toxicity, 
the duration of trastuzumab therapy, as per the NEMLC clinical 
criteria document, has been amended from 12 months to 6 months. 
The revised clinical criteria document for access to trastuzumab is 
shown in Fig. 1. Our hope is that this policy change, combined with 
substantial cost reductions through the availability of trastuzumab 
biosimilars, will be welcomed as a further advance for women’s 
health, as more eligible patients are able to access treatment with a 
reduced risk of harm.
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